• October 21, 2022

    The newest medicinal product to receive Marketing Authorization from the Medicines Executive Agency is:

    Semefro 50 mg/850 mg film-coated tablets

    Semefro 50 mg/1000 mg film-coated tablets

     

    Active ingredients: sitagliptin/metformin hydrochloride

     

    Semefro contains two different medicines called sitagliptin and metformin.

    – Sitagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors)

    – metformin belongs to a class of medicines called biguanidines.

     

    They work together to control blood sugar levels in adult patients with a form of diabetes called “type 2 diabetes”. This medication increases the levels of insulin produced after a meal and reduces the amount of sugar produced by the body.

     

    Along with diet and exercise, the drug helps lower blood sugar.

    The medication can be used alone or with certain other diabetes medications, (insulin, sulfonylurea, or glitazone).

     

    This is a prescription-only medicinal product.

     

    ATC code: A10BD07

  • October 19, 2022

    The turnover from transactions with Bulgarian shares reached just under BGN 6 million, and two-thirds of it (just over BGN 4 million) was formed by transactions with shares of Tchaikapharma High Quality Medicines. Another 4 companies formed another quarter of the turnover, SOFIX recorded a minimal decrease.

     

    Read the full article here in Bulgarian.

  • October 5, 2022

    Tchaikapharma has launched two new medicinal products on the market, which are already commercially available:

    Methylprednisolone-Chaikapharma (methylprednisolone) 40 mg powder and solvent for for injection solution

    TromBai (cilostazol) 100 mg tablets

     

    The distributor of the medicinal products is Commercial League – Global Pharmа Center.

  • July 8, 2022

    On July 7, 2022, the Bulgarian Credit Rating Agency (BCRA) has awarded the company with the highest market capitalization on the Bulgarian Stock Exchange Tchaikapharma a long-term credit rating of “BBB-” and a short-term “A” on a national scale. With this, BCRA expresses its opinion that the company maintains a very good financial position with low levels of indebtedness, high creditworthiness, formed satisfactory liquidity, allowing it to timely service its obligations. According to the BCRA’s rating scale, the rating assigned corresponds to an ‘investment grade’ credit rating.

    According to the agency’s analysis, the company is a well-established player in the local market with a long-standing (22 years) presence, a well-known name and reputation and an extensive commercial network.

  • July 4, 2022

    “Politicians in power have one main task – to create a competitive investment and business environment and deal with the growth of the national economy. The self-esteem of any nation is a product of GDP per capita. Politicians should focus on this issue.” This is what Tihomir Kamenov, a specialist in public and private law, founder of the company group Commercial League, the only Bulgarian senior member of the World Economic Forum in Davos, told BNR. Read more here.